Humacyte, Inc. — Form 8-K Summary
Reporting period and event: The report covers board appointments effective September 22, 2026. Humacyte announced them in a press release dated September 28, 2026.
Board appointments
- Scott Coward was appointed a Class I director, with a term expiring in 2028, and to the Audit Committee. His background includes public-company legal and executive leadership, corporate governance, mergers and acquisitions, and life sciences.
- Paul Kuznik was appointed a Class II director, with a term expiring in 2029, and to the Commercial Committee. His background includes medical technology leadership, vascular healthcare, commercialization, manufacturing, regulatory oversight, and integration.
Compensation and other disclosures
- Each director will receive a $50,000 annual cash retainer and $5,000 annually for board committee service, prorated for partial-year service in 2026.
- Each will receive an option to purchase 125,000 shares of Humacyte common stock. The filing does not specify the options’ exercise price or vesting terms.
- The filing reports no selection arrangements with other persons and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Financial results, outlook, and risks
This 8-K reports board appointments and director compensation; it does not provide revenue, profit, cash flow, margin, debt, liquidity, comparative-period results, guidance, or financial risk updates. The filing text does not provide financial values for these items.
Investor facts to verify
- Review the applicable equity compensation documents for option exercise price, vesting schedule, and potential dilution.
- Confirm the directors’ committee responsibilities and terms in subsequent company filings.
- Consult Humacyte’s periodic financial filings for current financial results, liquidity, and outlook, which are not addressed here.